Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial
Mary Gleesona b c d, Nicholas Counselle f, David Cunninghamb d✉, Anthony Lawriee f, Laura Clifton‐Hadleye f, Eliza Anne Hawkesg h i j, Andrew McMillank l, Kirit M. Ardeshnam n o p, Cathy Burtonq r, Nick Chadwicke f, Joanna Gambelle f,
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
We compared the International Prognostic Index (IPI), Revised (R)-IPI and age-adjusted (aa)-IPI as prognostic indices for patients with diffuse large B-cell lymphoma (DLBCL) in the UK National Cancer Research Institute (NCRI) R-CHOP 14 versus 21 trial (N = 1080). The R-IPI and aa-IPI showed no marked improvement compared to the IPI for overall and progression-free survival, in terms of model fit or discrimination. Similar results were observed in exploratory analyses incorporating the Grupo Español de Linfomas/Transplante de Médula Ósea (GELTAMO)-IPI, where baseline β2-microglobulin data were available (N = 655). Although our findings support current use of the IPI, a novel prognostic tool to better delineate a high-risk DLBCL group in the rituximab era is needed.
TL;DRAlthough the findings support current use of the IPI, a novel prognostic tool to better delineate a high‐risk DLBCL group in the rituximab era is needed. (Semantic Scholar)